ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies

Inglewood, California, May 12th, 2022 – ImaginAb Inc., a market-leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced a new agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro’s global core lab imaging service. In addition, the agreement allows Invicro to produce zirconium Zr 89 crefmirlimab for its preclinical offerings.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...